Compare DIN & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DIN | NBP |
|---|---|---|
| Founded | 1958 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 491.1M | 503.8M |
| IPO Year | 1991 | 2020 |
| Metric | DIN | NBP |
|---|---|---|
| Price | $36.86 | $3.80 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $30.67 | N/A |
| AVG Volume (30 Days) | 455.6K | ★ 714.5K |
| Earning Date | 11-05-2025 | 02-14-2026 |
| Dividend Yield | ★ 2.11% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.24 | N/A |
| Revenue | ★ $866,500,000.00 | N/A |
| Revenue This Year | $10.69 | N/A |
| Revenue Next Year | $2.20 | N/A |
| P/E Ratio | $16.12 | ★ N/A |
| Revenue Growth | ★ 6.47 | N/A |
| 52 Week Low | $18.63 | $0.60 |
| 52 Week High | $37.24 | $6.79 |
| Indicator | DIN | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 67.94 | N/A |
| Support Level | $31.26 | N/A |
| Resistance Level | $34.22 | N/A |
| Average True Range (ATR) | 1.29 | 0.00 |
| MACD | 0.14 | 0.00 |
| Stochastic Oscillator | 92.90 | 0.00 |
Dine Brands Global Inc owns and franchises thousands of restaurants under the Applebee's and International House of Pancakes names. Almost all company restaurants are located in the United States and franchised. Royalty revenue, which the company gets from franchisees based on franchisees' sales, accounts for roughly three-quarters of total company revenue. The company also earns revenue by leasing restaurant sites to franchisees. The company has four reportable segments Franchise operations, (an aggregation of Applebee's and IHOP franchise operations), Rental operations, Financing operations and Company-operated restaurant operations. The majority of revenue is derived from the Franchise operations segment.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.